ମୁଣ୍ଡ ଓ ବେକ କ୍ୟାନ୍ସର
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
କେଉଁଠିକୁ ଯିବେ
ଏହି trial ପାଇଁ ଭାରତରେ ୧ଟି hospital ରୋଗୀଙ୍କୁ ନେଉଛି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Sponsor: NATCO Pharma Ltd.
ClinicalTrials.gov ରେ NCT05283226
Last updated on the registry 23 Jan 2026 · read by us 20 Oct 2026